• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-1/PD-L1、CD8和FOXP3在胰腺导管腺癌中与促纤维增生性间质的预后价值、定位及相关性

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

作者信息

Diana Angela, Wang Lai Mun, D'Costa Zenobia, Allen Paul, Azad Abul, Silva Michael A, Soonawalla Zahir, Liu Stanley, McKenna W Gillies, Muschel Ruth J, Fokas Emmanouil

机构信息

Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.

Department of Pathology, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

出版信息

Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.

DOI:10.18632/oncotarget.10038
PMID:27329602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5173037/
Abstract

We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together with CD8+ tumor-infiltrating lymphocytes (TILs) and FOXP3+ Tregs in resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with adjuvant chemotherapy. Whole-mount FFPE tissue sections from 145 pancreatectomies were immunohistochemically stained for PD-1, PD-L1, CD8 and FOXP3. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin) and in regard to intratumoral lymphoid aggregates. The median OS was 21 months after a mean follow-up of 20 months (range, 2-69 months). In multivariate analysis, high PD-1+ TILs expression was associated with better OS (p = 0.049), LPFS (p = 0.017) and DMFS (p = 0.021). Similar findings were observed for CD8+ TILs, whereas FOXP3 and PD-L1 lacked prognostic significance. Although TIL distribution was heterogeneous, tumors of high stroma density had higher infiltration of CD8+ TILs than loose density stroma and vice versa (p < 0.001), whereas no correlation was found with stromal activity. Sixty (41.4%) tumors contained lymphoid aggregates and the presence of PD-1+ TILs was associated with better OS (p = 0.030), LPFS (p = 0.025) and DMFS (p = 0.033), whereas CD8+ TILs only correlated with superior LPFS (p = 0.039). PD-1+ and CD8+ TILs constitute independent prognostic markers in patients with PDAC treated with adjuvant chemotherapy. Our study provides important insight on the role of PD-1/PD-L1 in the context of desmoplastic stroma and could help guide future immunotherapies in PDAC.

摘要

我们研究了程序性细胞死亡蛋白1(PD-1)及其配体(PD-L1)、CD8+肿瘤浸润淋巴细胞(TILs)和FOXP3+调节性T细胞(Tregs)在接受辅助化疗的可切除胰腺导管腺癌(PDAC)样本中的预后价值。对145例胰腺切除术的全层福尔马林固定石蜡包埋(FFPE)组织切片进行PD-1、PD-L1、CD8和FOXP3的免疫组织化学染色。在考虑基质密度(苏木精-伊红染色)和活性(α-平滑肌肌动蛋白)以及肿瘤内淋巴样聚集物的情况下,将它们的表达与临床病理特征、总生存期(OS)、无进展生存期(PFS)、局部无进展生存期(LPFS)和无远处转移生存期(DMFS)相关联。平均随访20个月(范围2 - 69个月)后,中位OS为21个月。在多变量分析中,高PD-1+TILs表达与更好的OS(p = 0.049)、LPFS(p = 0.017)和DMFS(p = 0.021)相关。CD8+TILs也观察到类似结果,而FOXP3和PD-L1缺乏预后意义。尽管TIL分布不均一,但高基质密度肿瘤比低基质密度肿瘤有更高的CD8+TILs浸润(p < 0.001),而与基质活性无相关性。60例(41.4%)肿瘤含有淋巴样聚集物,PD-1+TILs的存在与更好的OS(p = 0.030)、LPFS(p = 0.025)和DMFS(p = 0.033)相关,而CD8+TILs仅与较好的LPFS相关(p = 0.039)。在接受辅助化疗的PDAC患者中,PD-1+和CD8+TILs构成独立的预后标志物。我们的研究为PD-1/PD-L1在促纤维增生性基质背景下的作用提供了重要见解,并有助于指导未来PDAC的免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d834/5173037/a029f1ea65a5/oncotarget-07-40992-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d834/5173037/b23d047b5520/oncotarget-07-40992-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d834/5173037/a029f1ea65a5/oncotarget-07-40992-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d834/5173037/b23d047b5520/oncotarget-07-40992-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d834/5173037/a029f1ea65a5/oncotarget-07-40992-g002.jpg

相似文献

1
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.PD-1/PD-L1、CD8和FOXP3在胰腺导管腺癌中与促纤维增生性间质的预后价值、定位及相关性
Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.
2
Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.CA9、CD31、CD68和CD20在胰腺导管腺癌中与促纤维增生性基质的预后作用及相关性
Oncotarget. 2016 Nov 8;7(45):72819-72832. doi: 10.18632/oncotarget.12022.
3
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.肿瘤浸润淋巴细胞、程序性细胞死亡配体-1、CD8 和 FOXP3 在三阴性乳腺癌预后模型中的整合:对 244 例接受标准治疗的 I-III 期患者的分析。
Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1.
4
The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.促纤维增生性间质在胰腺导管腺癌中的预后作用。
Oncotarget. 2016 Jan 26;7(4):4183-94. doi: 10.18632/oncotarget.6770.
5
Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.免疫因子在胰腺导管腺癌患者肿瘤微环境中的预后价值。
BMC Cancer. 2021 Nov 10;21(1):1197. doi: 10.1186/s12885-021-08911-4.
6
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).辅助放化疗后头颈癌患者的PD-1/PD-L1轴与人类乳头瘤病毒:德国癌症联盟放射肿瘤学组(DKTK-ROG)的多中心研究
Int J Cancer. 2017 Aug 1;141(3):594-603. doi: 10.1002/ijc.30770. Epub 2017 May 19.
7
PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.PD-1 高表达预示 IV 期 M0 鼻咽癌局部疾病控制率较低。
BMC Cancer. 2019 May 28;19(1):503. doi: 10.1186/s12885-019-5689-y.
8
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.PD-L1 和肿瘤浸润淋巴细胞在下咽鳞状细胞癌中的预后及临床病理意义。
Oral Oncol. 2020 Mar;102:104560. doi: 10.1016/j.oraloncology.2019.104560. Epub 2020 Jan 7.
9
A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.基于 PD-L2 的免疫标志物特征有助于预测可切除胰腺导管腺癌的生存情况。
J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0.
10
CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.基于预测性综合免疫比值的 CD25 和 TGF-β 阻断抑制胰腺癌肿瘤生长。
J Transl Med. 2018 Oct 25;16(1):294. doi: 10.1186/s12967-018-1673-6.

引用本文的文献

1
Prognostic Value of TBC1D1 and Its Relationship With the Tumor Microenvironment in Pancreatic Cancer: A Study Based on Single-Cell Sequencing.TBC1D1在胰腺癌中的预后价值及其与肿瘤微环境的关系:一项基于单细胞测序的研究
FASEB Bioadv. 2025 Jul 9;7(7):e70034. doi: 10.1096/fba.2025-00092. eCollection 2025 Jul.
2
Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer.人工智能助力的胰腺癌切除标本免疫表型空间分析
JAMA Surg. 2025 Jun 25. doi: 10.1001/jamasurg.2025.1999.
3
CRSP8-driven fatty acid metabolism reprogramming enhances hepatocellular carcinoma progression by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.

本文引用的文献

1
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.用于指导癌症治疗中免疫检查点阻断的机制驱动生物标志物。
Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15.
2
Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.胰腺导管腺癌的免疫和代谢特征定义了疾病的预后亚型。
Clin Cancer Res. 2016 Jul 15;22(14):3606-17. doi: 10.1158/1078-0432.CCR-15-1883. Epub 2016 Feb 8.
3
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
CRSP8驱动的脂肪酸代谢重编程通过抑制RAN介导的PPARα核质穿梭促进肝细胞癌进展。
J Exp Clin Cancer Res. 2025 Mar 11;44(1):93. doi: 10.1186/s13046-025-03329-3.
4
Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer.治疗前炎症性肿瘤免疫微环境与胰腺癌中FOLFIRINOX方案的反应相关。
Front Oncol. 2023 Nov 23;13:1274783. doi: 10.3389/fonc.2023.1274783. eCollection 2023.
5
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment.肿瘤内在的代谢重编程及其如何驱动对抗PD-1/PD-L1治疗的耐药性。
Cancer Drug Resist. 2023 Sep 4;6(3):611-641. doi: 10.20517/cdr.2023.60. eCollection 2023.
6
Early Increase in Circulating PD-1CD8 T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy.循环中PD-1⁺CD8⁺ T细胞早期增加预示接受化疗的晚期胃癌患者生存良好。
Cancers (Basel). 2023 Aug 3;15(15):3955. doi: 10.3390/cancers15153955.
7
The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.癌症相关成纤维细胞(CAFs)与免疫细胞在影响胰腺癌免疫治疗疗效中的探戈。
Int J Mol Sci. 2023 May 13;24(10):8707. doi: 10.3390/ijms24108707.
8
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer.胃癌中 PD-1 阳性 CD8 T 细胞的临床意义。
Gastric Cancer. 2023 May;26(3):393-404. doi: 10.1007/s10120-023-01364-7. Epub 2023 Feb 12.
9
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.探索胃肠道间质瘤中免疫系统与遗传学之间的动态相互作用。
Cancers (Basel). 2022 Dec 29;15(1):216. doi: 10.3390/cancers15010216.
10
Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma.表观遗传调控增强了胰腺导管腺癌的免疫治疗效果。
Clin Transl Immunology. 2022 Nov 28;11(12):e1430. doi: 10.1002/cti2.1430. eCollection 2022.
胃腺癌中PD-L1表达模式、CD8 T细胞浸润及相关免疫基质
Gut. 2017 May;66(5):794-801. doi: 10.1136/gutjnl-2015-310839. Epub 2016 Jan 22.
4
The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.促纤维增生性间质在胰腺导管腺癌中的预后作用。
Oncotarget. 2016 Jan 26;7(4):4183-94. doi: 10.18632/oncotarget.6770.
5
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.针对天然抗原设计的T细胞可克服免疫和物理屏障以治疗胰腺导管腺癌。
Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.
6
Classifying Cancers Based on T-cell Infiltration and PD-L1.基于T细胞浸润和PD-L1对癌症进行分类
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
7
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断:癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
8
Molecular landscape of pancreatic cancer: implications for current clinical trials.胰腺癌的分子图谱:对当前临床试验的启示
Oncotarget. 2015 Mar 10;6(7):4553-61. doi: 10.18632/oncotarget.2972.
9
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.诱导 T 细胞免疫克服对 PD-1 和 CTLA-4 阻断的完全抵抗并改善胰腺癌患者的生存。
Cancer Immunol Res. 2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.
10
Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.胰腺导管腺癌:从遗传学到生物学,再到放射生物学、肿瘤免疫学,最后回归临床。
Biochim Biophys Acta. 2015 Jan;1855(1):61-82. doi: 10.1016/j.bbcan.2014.12.001. Epub 2014 Dec 7.